Corytuberine

CAS No. 517-56-6

Corytuberine( ——— )

Catalog No. M39504 CAS No. 517-56-6

Corytuberine was inhibited only by naloxone and that of bulbocapnine preferentially by yohimbine.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 843 In Stock
25MG Get Quote In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Corytuberine
  • Note
    Research use only, not for human use.
  • Brief Description
    Corytuberine was inhibited only by naloxone and that of bulbocapnine preferentially by yohimbine.
  • Description
    Corytuberine was inhibited only by naloxone and that of bulbocapnine preferentially by yohimbine.
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    517-56-6
  • Formula Weight
    327.37
  • Molecular Formula
    C19H21NO4
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Spiroxamine

    Spiroxamine is a tertiary amine fungicide and an inhibitor of δ14 reductase and δ8→δ7 isomerase. Spiroxamine inhibits the growth of N. parvum, B. dothidea, D. seriata, and L. theobromae isolates from grape vines.

  • Corticotropin-releas...

    Corticotropin-releasing factor human (Human CRF; Human corticotropin-releasing factor) is an immunomodulatory neuropeptide that acts to release ACTH from the anterior pituitary and stimulates the sympathetic nervous system and adrenal medulla. Functions by reducing hyperpolarizations. Acts as a functional antagonist of inflammatory mediators.

  • Bentiromide

    Bentiromide is a peptide used in the bentiromide test to monitor the adequacy of supplemental pancreatic therapy and to screen exocrine pancreatic insufficiency.